Logo ActuIA ActuIA

AI news from France

Français Español Italiano Deutsch Nederlands Română Polski Português العربية Türkçe Українська 中文 日本語 한국어
Publish
Home
AI Watch

By category

Funding Mergers & acquisitions Model release Product launch Partnership Public program / call for projects Regulation & governance Litigation Research & science Deployment & adoption Infrastructure & compute Corporate & strategy Security & incident Report & study Event

By sector

Company Culture Defense Education Finance Fundamental Research Health - medicine Industry Insurance Justice Marketing Media Risk Prevention Social networks Telecommunications Transport

By category

Funding Mergers & acquisitions Model release Product launch Partnership Public program / call for projects Regulation & governance Litigation Research & science Deployment & adoption Infrastructure & compute Corporate & strategy Security & incident Report & study Event

By sector

Company Culture Defense Education Finance Fundamental Research Health - medicine Industry Insurance Justice Marketing Media Risk Prevention Social networks Telecommunications Transport
Latest news
Language

Genentech

Genentech Inc. est une société active dans le domaine de la biotechnologie. L'entreprise est connu grâce à ses recherches sur l'ADN recombinant. Aujourd'hui, ces recherches sont combinées à d'autres techniques mises au point par Genentech en vue de produire des médicaments de très haute technologie.

1 articles liés à cet acteur

Stanford University and Genentech introduced Trial Pathdfinder, a clinical trial support system

Stanford University and Genentech introduced Trial Pathdfinder, a clinical trial support system

Clinical trials are fundamental for researchers to test the efficacy and tolerance of patients to a treatment. The selection of people for these trial...

Apr 13, 2021 Read more →
Logo ActuIA Logo ActuIA

Your source of information on artificial intelligence and its advances.

Navigation

  • Legal notice
  • Contact

Follow us

© 2019-2026 Net Square Digital. All rights reserved.